Roche Expands Liver Treatment Portfolio with $3.5B Acquisition

Basel-based pharmaceutical giant Roche has announced a significant expansion of its liver treatment portfolio through the acquisition of California-based 89bio. The deal, valued at up to $3.5 billion, marks one of Roche's strategic moves to strengthen its position in the treatment of liver and cardiovascular disorders. The acquisition has received approval from both companies' supervisory bodies and is expected to be completed before the end of 2025.

The acquisition represents a strategic enhancement of Roche's therapeutic portfolio, particularly in the liver disease segment. A key asset in the acquisition is pegozafermin, 89bio's leading drug candidate currently in Phase III clinical trials for treating hepatic steatosis linked to metabolic dysfunction. This addition strengthens Roche's position in addressing unmet medical needs in liver diseases, a growing concern globally.

The transaction structure includes an initial payment of $2.4 billion (CHF1.9 billion), with potential additional payments of up to $1.1 billion. Roche's offer of $6 per share represents a substantial premium of 52% over 89bio's 60-day weighted average trading price, and a 79% premium over the closing price on September 17. This valuation reflects Roche's confidence in 89bio's pipeline and potential market impact.

Following the completion of the acquisition, 89bio's employees will be integrated into Roche's pharmaceutical workforce, bringing their expertise in liver and cardiovascular disorders. The integration plan focuses on maintaining research continuity, particularly for the ongoing Phase III clinical trials of pegozafermin. This merger of talent and resources is expected to accelerate the development and commercialization of innovative treatments.

The acquisition strengthens Switzerland's position as a global pharmaceutical hub and reinforces Roche's commitment to innovation in healthcare. The deal is expected to have significant implications for the liver disease treatment market, where there is growing demand for effective therapies. From a Swiss perspective, this acquisition demonstrates the continued dynamism of the country's pharmaceutical sector and its ability to lead in global healthcare innovation.